Grail's uphill battle to get Medicare to pay for cancer screening test; GSK settles in cancer lawsuit case

Grail's controversial blood test Galleri, which screens for multiple cancers, has not yet been approved by the FDA.

June 27, 2023 Check out STAT+

Sponsored By

Grail STAT+ | Grail faces uphill battle to get Medicare to cover its cancer screening test Medicare doesn't usually cover tests that screen healthy people, as Grail's cancer screening test Galleri does. By John Wilkerson STAT+ | GSK settles first lawsuit set for a U.S. trial over cancer links to Zantac The lawsuit argued GSK knew the active ingredient in Zantac, which is called ranitidine, degraded and transformed into a potential carcinogen By Ed Silverman STAT+ | ADA says all diabetes patients should be screened for nonalcoholic fatty liver disease The ADA singled out GLP-1 treatments as an option doctors could consider to treat nonalcoholic fatty liver disease. By Elaine Chen

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser